Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
The Vanguard Group, Inc. (IRSH)
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
01-Jun-2023 / 12:48 GMT/BST
Ap27
FORM 8.3
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
Full name of discloser
The Vanguard Group, Inc.
Owner or controller of interests and short positions disclosed, if different from 1(a)The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
Name of offeror/offeree in relation to whose relevant securities this form relates
Use a separate form for each offeror/offeree
Horizon Therapeutics plc
If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)Date position held/dealing undertaken
For an opening position disclosure, state the latest practicable date prior to the disclosure
31 May 2023
In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?If it is a cash offer or possible cash offer, state “N/A”
N/A
2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.
Ap28
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
(Note 2)
Class of relevant security
(Note 3)
US$0.0001 ordinary shares
Interests
Short positions
Number
%
Number
%
Relevant securities owned and/or controlled21,558,630
9.42%
Cash-settled derivatives
Stock-settled derivatives (including options) and agreements to purchase/ sell
Total
21,558,630
9.42%
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security
Purchase/sale
Number of securities
Price per unit
(Note 5)
US$0.0001 ordinary shares
Purchase
10,963
100.03 USD
US$0.0001 ordinary shares
Sale
42,070
100.03 USD
Ap29
(b) Cash-settled derivative transactions
Class of
relevant
security
Product
description
e.g. CFD
Nature of dealing
e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position
Number of
reference
securities
(Note 6)
Price
per unit
(Note 5)
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of
relevant
security
Product
description e.g. call
Writing, purchasing, selling, varying
etc.
Number
of
securities
to which
relates
(Note 6)
Exercise
price per
unit
Type
e.g.
American,
European
etc.
Expiry
date
money
paid/
received per unit
(ii) Exercise
Class of
relevant
security
Product
description
e.g. call
Exercising/
exercised
against
Number of
securities
Exercise
price per
unit
(Note 5)
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Class of
relevant
security
Nature of dealing
e.g. subscription,
conversion, exercise
Details
Price per unit (if
applicable)
(Note 5)
Not Applicable
Ap30
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
none
(b) Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
none
(c) Attachments
Is a Supplemental Form 8 attached?
No
Date of disclosure
01 June 2023
Contact name
Shawn Acker
Telephone number
001-610-669-6713
Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
Category Code: RET - Horizon Therapeutics plc TIDM: IRSH LEI Code: 5493002789CX3L0CJP65 Sequence No.: 248011 EQS News ID: 1647479
End of Announcement EQS News Service